Fusobacterium nucleatum (F. nucleatum) is a common type of bacteria that proliferates in periodontal disease. It affects the gums and jawbone, and if untreated results in unstable teeth and tooth loss. In recent years, F. ...
Jul 12, 2022
0
24
Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.
Apr 7, 2022
0
507
Neuroblastoma accounts for 15% of total childhood cancer deaths. The survival rate of high-risk neuroblastoma patients is 50%.
Jul 26, 2019
0
2278
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified potent, highly specific compounds that interfere with bromodomain (BD)-containing proteins involved in cancer. The compounds, called ...
Jun 3, 2022
0
142
Researchers from the University of Minnesota have discovered that a protein associated with metabolism, and formerly recognized as a potential therapeutic target for ovarian cancer, may instead be associated with a better ...
Jul 20, 2022
0
9
An international group of researchers investigated why mutations often associated with renal cancer result specifically in renal cancer, instead of other cancer types.
Aug 9, 2022
0
85
UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.
Jul 25, 2011
0
0
Researchers at the University of Arizona College of Medicine–Tucson, along with collaborators at Harvard University, harnessed the power of artificial intelligence to identify causes of Alzheimer's disease and potential ...
May 16, 2023
0
129
Cancer cells can change shape to travel around the body and spread (metastasize), but how they know when to do this has remained elusive.
Apr 17, 2024
0
33
The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer's drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer's disease.
Nov 15, 2022
0
2
